NorthWest Biotherapeutics Inc (NWBO)

[barnstormer]

Slave, thanks for your detailed input as always. But it does address an ongoing question I've had that I'd appreciate your input on, namely when does a variation not part of the initial MAA need to be made public. In particular, if it expands the MAA to include treatment of other forms of cancer and/or inclusion of the EDEN system, is the addition not required to be made public since it may have a significant impact on the share price? Not talking about providing anything that impacts MHRA process, just an announcement by the company the variation has been filed.